A Smoking Cessation Intervention for Yale Dining Employees

Yale University

Status and phase: Completed; Phase 4

Conditions: Smoking Cessation

Treatments: Behavioral: Contingency management; Drug: Nicotine replacement therapy; Behavioral: Additional behavioral support; Drug: Varenicline

Study type: Interventional

Funder types: Other

Identifiers

NCT02562521

1411014980

Details and patient eligibility

About

The purpose of this study is to evaluate a smoking cessation program for employees at the Yale University dining hall. Two pilot dining halls and six paired dining halls (3 test and 3 control sites) will be offered a contingency management/pharmacotherapy smoking cessation intervention at the work site.

Full description

The primary aim of this study is to test the effect of a smoking cessation intervention provided to Yale University dining hall employees on smoking quit rates and quit attempts at the end of six weeks of treatment. It is hypothesized that participants from the test site will have higher rates of smoking cessation and quit attempts compared to participants from the control site. In addition, this study will examine the number of participants who enroll in the smoking cessation program who successfully quit smoking at 6 months.

There will be 3 test sites and 3 control sites in this study (broken down into 3 pairs of test/control). Each test site will be matched to on a control site. Self-reported smoking status will be obtained for all participants in the test and control sites at 3 time points (baseline, 6 weeks and 6 months). The study start time for each pair will be delayed by 4-8 weeks for feasibility issues.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Current smoker
• Interested in receiving treatment for quitting smoking.
• Employed for more than 20 hours per week by one of the 7 residential college dining halls selected for inclusion in this study.
• English speaker.

Exclusion criteria

• None specified, other than failure to meet all inclusion criteria listed above.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

25 participants in 2 patient groups

Smoking Cessation Treatment

Experimental group

Description:

The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy \[NRT\] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.

Treatment:

Drug: Varenicline

Behavioral: Additional behavioral support

Behavioral: Contingency management

Drug: Nicotine replacement therapy

Delayed Treatment Control

No Intervention group

Description:

Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later